ATE285791T1 - Impfstoff, der acemannan als adjuvans enthält - Google Patents

Impfstoff, der acemannan als adjuvans enthält

Info

Publication number: ATE285791T1
Authority: AT; Austria
Prior art keywords: effective; amount; immunizing; modified live; provides
Prior art date: 1992-01-17

Application number

AT93903565T

Other languages

English (en)

Inventor

Robert M Nordgren

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-01-17

Filing date

1993-01-15

Publication date

2005-01-15

1993-01-15 Application filed by Wyeth Corp filed Critical Wyeth Corp

2005-01-15 Application granted granted Critical

2005-01-15 Publication of ATE285791T1 publication Critical patent/ATE285791T1/de

Links

XOYXESIZZFUVRD-UVSAJTFZSA-M acemannan Chemical compound CC(=O)O[C@@H]1[C@H](O)[C@@H](OC)O[C@H](CO)[C@H]1O[C@@H]1[C@@H](O)[C@@H](OC(C)=O)[C@H](O[C@@H]2[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]3[C@H]([C@@H](O)[C@H](O[C@@H]4[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]5[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]6[C@H]([C@@H](OC(C)=O)[C@H](O[C@@H]7[C@H]([C@@H](OC(C)=O)[C@H](OC)[C@@H](CO)O7)O)[C@@H](CO)O6)O)[C@H](O5)C([O-])=O)O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](CO)O2)O)[C@@H](CO)O1 XOYXESIZZFUVRD-UVSAJTFZSA-M 0.000 title abstract 4
229960005327 acemannan Drugs 0.000 title abstract 4
229960005486 vaccine Drugs 0.000 title abstract 4
239000002671 adjuvant Substances 0.000 title 1
230000003053 immunization Effects 0.000 abstract 7
241000700605 Viruses Species 0.000 abstract 4
230000005847 immunogenicity Effects 0.000 abstract 4
241001502481 Meleagrid alphaherpesvirus 1 Species 0.000 abstract 3
241001465754 Metazoa Species 0.000 abstract 2
239000000427 antigen Substances 0.000 abstract 2
102000036639 antigens Human genes 0.000 abstract 2
108091007433 antigens Proteins 0.000 abstract 2
230000001580 bacterial effect Effects 0.000 abstract 2
208000035143 Bacterial infection Diseases 0.000 abstract 1
208000006758 Marek Disease Diseases 0.000 abstract 1
208000022362 bacterial infectious disease Diseases 0.000 abstract 1
150000001720 carbohydrates Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000003612 virological effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/0241—Mollicutes, e.g. Mycoplasma, Erysipelothrix
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A61K39/255—Marek's disease virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
- C12N2710/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/10011—Birnaviridae
- C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT93903565T 1992-01-17 1993-01-15 Impfstoff, der acemannan als adjuvans enthält ATE285791T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82253092A	1992-01-17	1992-01-17
PCT/US1993/000450 WO1993014195A1 (en)	1992-01-17	1993-01-15	Vaccine containing acemannan as an adjuvant

Publications (1)

Publication Number	Publication Date
ATE285791T1 true ATE285791T1 (de)	2005-01-15

Family

ID=25236286

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT93903565T ATE285791T1 (de)	1992-01-17	1993-01-15	Impfstoff, der acemannan als adjuvans enthält

Country Status (10)

Country	Link
EP (1)	EP0626008B1 (de)
JP (1)	JP3723205B2 (de)
AT (1)	ATE285791T1 (de)
AU (1)	AU3478393A (de)
DE (1)	DE69333730T2 (de)
DK (1)	DK0626008T3 (de)
ES (1)	ES2236685T3 (de)
IL (1)	IL104382A0 (de)
WO (1)	WO1993014195A1 (de)
ZA (1)	ZA93216B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5106616A (en) *	1988-01-14	1992-04-21	Carrington Laboratories, Inc.	Administration of acemannan
AUPM322393A0 (en) *	1993-12-24	1994-01-27	Austin Research Institute, The	Mucin carbohydrate compounds and their use in immunotherapy
US6548643B1 (en)	1994-11-16	2003-04-15	Austin Research Institute	Antigen carbohydrate compounds and their use in immunotherapy
US8021667B2 (en)	1994-11-16	2011-09-20	Macfarlane Burnet Institute For Medical Research And Public Health Ltd	Compositions for immunotherapy and uses thereof
IT1276509B1 (it) *	1995-03-31	1997-10-31	Istituto Superiore Della Sanit	Vaccino per la profilassiimmunitaria dell'infezione da virus della immunodeficienza felina del gatto domestico.
CU22629A1 (es) *	1997-03-06	2000-12-22	Ct Ingenieria Genetica Biotech	Formulaciones inmunopotenciadoras para uso vacunal
DK1027063T3 (da)	1997-09-29	2009-06-02	Macfarlane Burnet Inst For Med	Mannosereceptorbærende cellelinje og antigensammensætning
CU22740A1 (es) *	1998-09-07	2002-02-28	Ct Ingenieria Genetica Biotech	Formulación de ácidos nucleicos y acemanano
WO2004060265A2 (en)	2003-01-07	2004-07-22	Yeda Research And Development Co. Ltd.	Eye-drop vaccine containing copolymer 1 for therapeutic immunization
CN111542337A (zh) *	2017-12-20	2020-08-14	英特维特国际股份有限公司	用于细胞相关联的α疱疹病毒疫苗的改良稀释剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5106616A (en) *	1988-01-14	1992-04-21	Carrington Laboratories, Inc.	Administration of acemannan
EP0173997A1 (de) *	1984-09-06	1986-03-12	Chiron Corporation	Katzenleukämievirusproteinimpfstoffe und ihre Herstellung
CA1337268C (en) *	1987-03-09	1995-10-10	Edmund P. Bass	Canine distemper virus vaccine
JP2779447B2 (ja) *	1988-03-20	1998-07-23	財団法人阪大微生物病研究会	弱毒マレック病ウイルス・ベクターを用いる組換え遺伝子作成法、及び該ウイルスの組換え体
DE68929419T2 (de) *	1988-12-13	2003-04-03	Colorado State University Research Foundation, Fort Collins	Prototypische FeLV-Isolate für die Verwendung als Krankheitsmuster oder Impfstoff
US5032401A (en) *	1989-06-15	1991-07-16	Alpha Beta Technology	Glucan drug delivery system and adjuvant
US5118502A (en) *	1989-06-20	1992-06-02	The University Of Georgia Research Foundation, Inc.	Naturally attenuated newcastle disease vaccine and method of using the same
AU641958B2 (en) *	1989-10-02	1993-10-07	University Of Arkansas, The	Method of producing active immunity against a viral disease
EP0423869B1 (de) *	1989-10-20	1995-07-12	Akzo Nobel N.V.	Impfstoff gegen IBV
WO1993008810A1 (en) *	1991-11-05	1993-05-13	Carrington Laboratories, Inc.	Uses of aloe products, e.g. acemannan, in the treatment of diseases requiring intervention of the immune system for cure

1993
- 1993-01-13 IL IL104382A patent/IL104382A0/xx not_active IP Right Cessation
- 1993-01-13 ZA ZA93216A patent/ZA93216B/xx unknown
- 1993-01-15 AT AT93903565T patent/ATE285791T1/de not_active IP Right Cessation
- 1993-01-15 JP JP51270393A patent/JP3723205B2/ja not_active Expired - Fee Related
- 1993-01-15 ES ES93903565T patent/ES2236685T3/es not_active Expired - Lifetime
- 1993-01-15 AU AU34783/93A patent/AU3478393A/en not_active Abandoned
- 1993-01-15 DE DE69333730T patent/DE69333730T2/de not_active Expired - Fee Related
- 1993-01-15 DK DK93903565T patent/DK0626008T3/da active
- 1993-01-15 EP EP93903565A patent/EP0626008B1/de not_active Expired - Lifetime
- 1993-01-15 WO PCT/US1993/000450 patent/WO1993014195A1/en not_active Ceased

Also Published As

Publication number	Publication date
EP0626008B1 (de)	2004-12-29
AU3478393A (en)	1993-08-03
DE69333730T2 (de)	2005-12-15
IL104382A0 (en)	1993-05-13
JPH07506565A (ja)	1995-07-20
ES2236685T3 (es)	2005-07-16
EP0626008A1 (de)	1994-11-30
EP0626008A4 (en)	1995-11-15
WO1993014195A1 (en)	1993-07-22
JP3723205B2 (ja)	2005-12-07
ZA93216B (en)	1993-08-18
DE69333730D1 (de)	2005-02-03
DK0626008T3 (da)	2005-05-02

Legal Events

Date

Code

Title

Description

2005-10-15

UEP

Publication of translation of european patent specification

Ref document number: 0626008

Country of ref document: EP

2009-10-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
DE69225471D1 (de)	1998-06-18	Abgeschwächtes, gentechnologisch hergestelltes pseudorabies virus s-prv-155 und seine verwendungen
NO871313D0 (no)	1987-03-27	Fremgangsmaate for fremstilling av virusvaksine.
NO931372D0 (no)	1993-04-14	Behandling av autoimmunsykdommer ved oral administrering av autoantigener
ES2152292T3 (es)	2001-02-01	Vacuna para aves de corral que contiene el virus de la bronquitis infecciosa 4/91.
DE69333730D1 (de)	2005-02-03	Impfstoff, der acemannan als adjuvans enthält
ATE200735T1 (de)	2001-05-15	Impfstoffkonjugat
KR100218138B1 (en)	1999-09-01	Methods and vaccines comprising surface-active copolymers
IE940698L (en)	1985-10-05	Vaccine and serum for endotoxin associated disease and method of preparing same as well as to methods of immunization and treatment of such disease and to a detoxified endotoxin and bacterial mutant
HUP0104125A2 (hu)	2002-03-28	Eljárás szárnyasok intradermális immunizálására inaktivált vakcinákkal
MX9301736A (es)	1994-01-31	Vacuna de bacterina-toxoide de pasteurella haemolytica tipo a-1.
ZA908260B (en)	1991-08-28	Infectious bursal disease virus
WO2004100640A3 (en)	2006-01-19	Marek’s disease virus vaccine
BR9814556A (pt)	2000-10-17	Cepas isoladas de staphylococcus aureus e vacinas fabricadas a partir das mesmas
NZ243251A (en)	1993-11-25	Vaccine against marek's disease virus in poultry
ZA859428B (en)	1987-08-26	Biological preparations
Sivanandan et al.	1993	Protective efficacy of a adjuvanted Newcastle disease virus vaccine A et al.
FI972658L (fi)	1997-06-19	Menetelmä rokotteen valmistamiseksi siipikarjan tarttuvaa bursaalitautia vastaan
Dardanoni et al.	1986	Vaccination against hepatitis B: Evaluation of the prevaccination markers.
李啓仁	1994	New Vaccine Technologies, Adjuvants and Delivery System
Koesters	1983	Vaccination of parent poultry flocks.